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Atrial fibrillation (AF) and sinus bradycardia have been reported in patients with short QT
syndrome variant 2 (SQT2), which is underlain by gain-of-function mutations in KCNQ1
encoding the α subunit of channels carrying slow delayed rectifier potassium current,
IKs. However, the mechanism(s) underlying the increased atrial arrhythmogenesis and
impaired cardiac pacemaking activity arising from increased IKs remain unclear. Possible
pharmacological interventions of AF in the SQT2 condition also remain to be elucidated.
Using computational modelling, we assessed the functional impact of SQT2 mutations
on human sinoatrial node (SAN) pacemaking, atrial repolarisation and arrhythmogenesis,
and efficacy of the anti-arrhythmic drug quinidine. Markov chain formulations of IKs
describing two KCNQ1 mutations – V141M and V307L – were developed from voltage-
clamp experimental data and then incorporated into contemporary action potential (AP)
models of human atrial and SAN cells, the former of which were integrated into idealised
and anatomically detailed tissue models. Both mutations shortened atrial AP duration
(APD) through distinct IKs ‘gain-of-function’ mechanisms, whereas SAN pacemaking
rate was slowed markedly only by the V141M mutation. Differences in APD restitution
steepness influenced re-entry dynamics in tissue – the V141M mutation promoted
stationary and stable spiral waves whereas the V307L mutation promoted non-
stationary and unstable re-entrant waves. Both mutations shortened tissue excitation
wavelength through reduced effective refractory period but not conduction velocity,
which served to increase the lifespan of re-entrant excitation in a 3D anatomical
human atria model, as well as the dominant frequency (DF), which was higher for the
V141M mutation. Quinidine was effective at terminating arrhythmic excitation waves
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associated with the V307L but not V141M mutation, and reduced the DF in a dose-
dependent manner under both mutation conditions. This study provides mechanistic
insights into different AF/bradycardia phenotypes in SQT2 and the efficacy of quinidine
pharmacotherapy.
Keywords: anti-arrhythmic, arrhythmia, short QT syndrome, atrial fibrillation, KCNQ1 mutations, sinus
bradycardia, quinidine
INTRODUCTION
The short QT syndrome (SQTS) is a rare but important cardiac
disorder characterised by a shortened QT interval, increased
incidence of ventricular and atrial arrhythmias, and risk of
sudden death in affected patients (Schimpf et al., 2005). Variants
1–3 of the SQTS are caused by gain-of-function mutations
to genes encoding different K+ channel subunits, which carry
currents responsible for phase 3 repolarisation of the cardiac
action potential (AP) (Hancox et al., 2018). Mutations to
the KCNQ1 (KvLQT1, Kv7.1) gene product which, along with
auxiliary subunits encoded by KCNE1, encodes slow delayed
rectifier potassium current, IKs, underlie SQTS variant 2 (SQT2).
To date, four missense mutations have been identified in KCNQ1-
linked SQTS: V307L (Bellocq et al., 2004), V141M (Hong et al.,
2005), R259H (Wu et al., 2015), and F279I (Moreno et al., 2015),
all of which result in a gain-of-function of IKs.
There is mounting evidence for a role of IKs in atrial
arrhythmogenesis (Christophersen and Ellinor, 2016).
Upregulation of IKs has been identified in patients with
chronic atrial fibrillation (AF) (Caballero et al., 2010; González
de la Fuente et al., 2013), and mutations to KCNQ1 have been
shown to underlie lone AF (Chen et al., 2003; Lundby et al.,
2007; Das et al., 2009). These findings suggest that enhanced
IKs may play a role in the pathogenesis of AF. In some SQT2
patients, cardiac arrhythmia including AF has been reported
(Hong et al., 2005; Villafañe et al., 2014; Righi et al., 2016).
However, the mechanism(s) underlying atrial arrhythmogenesis
and maintenance arising from increased potassium channel
currents, including IKs, remain to be fully established. The SQTS
thus represents a valuable paradigm for investigating the role of
K+ channels in AF.
Atrial fibrillation can be the first clinical presentation of the
SQTS, particularly in patients diagnosed with lone AF (Hasdemir,
2016). Furthermore, the incidence of AF has been reported to be
higher in patients with SQT2 than other forms of SQTS (63%
vs. 21%, p = 0.012 (Harrell et al., 2015)). The first reported
SQT2 mutation, V307L KCNQ1 (Bellocq et al., 2004), was
shown to shift the voltage-dependence of KCNQ1 + KCNE1
activation toward less depolarised potentials and accelerate
channel activation, causing a gain-of-function to IKs. The
proband presented with a shortened QTc interval and idiopathic
ventricular fibrillation (Bellocq et al., 2004) – whether or not
this mutation is able also to promote AF is not yet known. The
subsequently discovered V141M KCNQ1 mutation differs from
the V307L KCNQ1 mutation in that it induces an instantaneous,
voltage-independent K+-selective current component (Hong
et al., 2005). This form of SQT2 is associated with abnormally
short QT intervals in affected patients, as well as multiple reports
of a mixed AF and sinus bradycardia phenotype (Hong et al.,
2005; Villafañe et al., 2014; Righi et al., 2016).
At present, there are no phenotypically accurate experimental
models of genetic forms of SQTS. Computational modelling
offers a viable way of investigating how SQTS-linked K+
channelopathies affect organ scale electrical propagation
and arrhythmogenesis. Previous studies have investigated
the functional impact of SQT2 variants on ventricular
arrhythmogenesis (Zhang et al., 2008; Adeniran et al., 2017),
which can be attributed to abbreviated ventricular AP duration
(and therefore excitation wavelength), increased transmural
dispersion of repolarisation, and increased vulnerability of
tissue to initiation of unidirectional conduction block. However,
the mechanism(s) by which SQT2 variants promote atrial
arrhythmogenesis has not been elucidated – it is possible that
the interaction between genetic mutations and intrinsic electrical
heterogeneities in the human atria may form an important
determinant of arrhythmogenic mechanisms, as shown in
previous studies (Colman et al., 2017; Whittaker et al., 2017b).
Consequently, the first aim of this study was to dissect underlying
mechanisms of increased susceptibility to development of AF
associated with SQT2 using both idealised and anatomically-
detailed, heterogeneous multi-scale tissue models of human
atrial electrophysiology. We chose to study the V141M KCNQ1
mutation, which has been linked with multiple reports of AF
(Hong et al., 2005; Villafañe et al., 2014; Righi et al., 2016),
and use the V307L KCNQ1 mutation as a comparator, which
has distinct kinetics and has been demonstrated to promote
ventricular arrhythmogenesis in our previous computational
modelling study (Adeniran et al., 2017).
Effective pharmacological management of AF in KCNQ1-
linked SQTS conditions is an unmet challenge. Quinidine – an
established inhibitor of SQTS mutant hERG channels (Gaita
et al., 2004; Hu et al., 2017) has shown some efficacy in the
ventricles in non-hERG-linked SQTS (e.g., Giustetto et al., 2011).
However, its anti-AF effects in the context of SQT2 remain
unclear. The second aim of this study was thus to assess the
effects of quinidine on arrhythmic atrial excitation waves in SQT2
using cellular and tissue level simulations that incorporated drug
binding kinetics and multi-channel pharmacology.
MATERIALS AND METHODS
Markov Chain Models of IKs
A Markov chain (MC) formulation of human cardiac IKs
(Silva and Rudy, 2005; Adeniran et al., 2017) was used to
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simulate IKs in wild type (WT) and SQT2 mutation conditions
(MC scheme shown in Supplementary Figure S1). The V307L
KCNQ1 mutation MC formulation has been described and
validated previously (Adeniran et al., 2017); nonetheless, for
completeness, the response of WT and V307L mutant currents
to simulated voltage clamps – namely the I–V relation and
steady state activation – and human atrial AP clamp is shown in
Supplementary Figure S2.
The MC formulation of IKs was subsequently employed
to develop a model of the V141M mutation in KCNQ1,
first described by Hong et al. (2005). Multi-objective fitting
to experimental data (Restier et al., 2008), namely the I–V
relation, steady state activation, and voltage clamp current
traces, was performed using a bounded Nelder–Mead simplex
algorithm (Moreno et al., 2016). As experimental data were
acquired at room temperature, a Q10 correction value of 3.5
(Seebohm et al., 2001) was applied in order to represent
kinetics at physiological temperature. An additional voltage-
independent parameter, ξ , was introduced to account for the
constitutively active component of IKs observed in KCNQ1
V141M mutant channels (Hong et al., 2005; Restier et al.,
2008). The response of V141M mutant currents to simulated
voltage clamps and corresponding I–V relation and steady
state activation is shown in Figure 1. The V141M mutant IKs
formulation reproduced accurately the experimentally measured
I–V relationship and voltage dependence of activation under
voltage clamp conditions, as well as faster activation and slower
deactivation (Restier et al., 2008). For both mutations, in order
to mimic the heterozygous state of probands, a heterozygous
mutation formulation consisting of 50% WT and 50% mutant
subunit channels was constructed (Adeniran et al., 2017). For
more details of the MC scheme, see Supplementary Method 1.1.
Modelling Electrophysiology of the
Human Atria and Sinoatrial Node
The Colman et al. (2013) family human atrial cell models
incorporating regional heterogeneity, recently updated by Ni
et al. (2017), was used to simulate human atrial electrophysiology
in this study, and is hereinafter referred to as the CNZ (Colman-
Ni-Zhang) model. For all single cell, 1D, and 2D simulations
the baseline right atrium (RA) model was used. The equations
for IKs – which are native to the parent Courtemanche-
Ramirez-Nattel (CRN) model (Courtemanche et al., 1998) –
were replaced with that of the WT MC formulation, with a
current density within the range measured in human atrial
myocytes (Caballero et al., 2010) – Supplementary Figure S4.
Furthermore, as a theoretical consideration, the effects of AF-
induced electrical remodelling (Supplementary Figure S6) were
incorporated into supplementary CNZ model simulations, to
assess the combined influence of KCNQ1 mutations and AF
remodelling. A recently developed human sinoatrial node (SAN)
model (Fabbri et al., 2017), hereinafter referred to as the FS
(Fabbri-Severi) model, was used to simulate the AP of primary
pacemaker cells in the human heart. The native equations for IKs
were replaced by the WT MC IKs formulation – Supplementary
Figure S7 shows the agreement between the modified FS model
AP and published experimental recordings from human SAN
myocytes (Verkerk et al., 2007). Full details of the CNZ and
FS models, including definitions of quantitative AP biomarkers
used, the effects of the new IKs formulation on the AP, regional
human atrial electrophysiology models, AF remodelling, and
parasympathetic modulation with acetylcholine (ACh), can be
found in Supplementary Method 1.2–1.4.
Modelling Pharmacological Actions of
Quinidine
In our recent prior study (Whittaker et al., 2017a), state-
dependent binding of quinidine to hERG and sodium channels
was simulated in human ventricle models. Secondary blocking
actions of quinidine on other affected ionic currents were
described using a simple pore block approach. The actions of
quinidine on human atrial cells in this study were represented
using the same formulations and IC50 (half maximal inhibitory
concentration) values (Whittaker et al., 2017a). Additionally,
quinidine block of the atrial-specific ultra-rapid delayed rectifier
potassium current, IKur, was incorporated into CNZ simulations
with an IC50 of 6.6 µM (Nenov et al., 1998), as measured
in human atrial myocytes. Concentrations of 1, 2, and 5 µM
quinidine, which likely represent realistic maximal unbound
concentrations (Whittaker et al., 2017a), were used. A summary
of IC50 values for quinidine inhibition of multiple ion
channels is given in Supplementary Table S4. Further details
regarding kinetics, parameters, and equations can be found
in Supplementary Method 1.5, as well as our previous study
(Whittaker et al., 2017a).
Tissue Simulations
The effects of SQT2 mutations on human atrial electrophysiology
were further investigated using a hierarchy of tissue models.
One-dimensional (1D) models of human atrial strands were
used to assess the effects of KCNQ1 mutations on the effective
refractory period (ERP), conduction velocity (CV), and excitation
wavelength (WL). In order to characterise re-entrant excitation
wave dynamics, an isotropic 2D sheet of human atrial tissue
was used, wherein spiral waves were initiated using an S1–
S2 cross-field protocol (Whittaker et al., 2017b). In order
to characterise the lifespan and dominant frequency (DF)
of arrhythmic excitation waves, as well as the response to
quinidine, a 3D anatomical model of the human atria (Seemann
et al., 2006; Colman et al., 2013) with heterogeneity of
electrophysiology, rule-based fibre orientations (Krueger et al.,
2011), and validated activation times was used (Supplementary
Figure S10). Scroll waves were initiated proximal to the SAN
in the RA using the phase distribution method (Biktashev
and Holden, 1998; Colman et al., 2017; Whittaker et al.,
2017b), which developed into functional and/or anatomical re-
entries in the 3D anatomical human atria model. The rate of
electrical activation during re-entrant excitation was determined
from pseudo-ECG (pECG) signals. It should be noted that
the SAN region was modelled electrically as CT tissue in 3D
simulations for simplicity (Colman et al., 2013, 2017). Further
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FIGURE 1 | Kinetics of the V141M KCNQ1 mutant IKs model. A comparison of simulated voltage clamp current traces in WT (Ai) and V141M (Aii) conditions at
22◦C. Experimental traces inset are reproduced with permission from Restier et al. (2008), which describes the protocols used. Simulated (solid lines) I–V relation (B)
and voltage dependence of activation (C) under WT and V141M mutation conditions, compared with experimental data (points).
descriptions of tissue models and simulation protocols are given
in Supplementary Methods 1.6–1.9.
RESULTS
Modification of Human SAN Cell
Pacemaking by SQT2 Mutant IKs
The effects of KCNQ1 V141M and V307L gain-of-function
mutations on IKs were first investigated in the FS SAN model
(Figure 2). The heterozygous form of the V141M mutation
decreased the diastolic depolarisation rate (DDR) due to
increased repolarising current at potentials negative to the take-
off (threshold) potential, which extended the pacemaker potential
and reduced the beating rate of single SAN cells from 73 bpm
in the WT condition to 50 bpm. The homozygous condition
abolished pacemaking, as increased repolarising IKs prevented
the membrane potential from reaching the take-off potential. The
APD90 in the WT-V141M condition was reduced from 151.4 ms
in the WT condition to 143.4 ms. The effects of the V307L
mutant were comparatively modest; the WT-V307L and V307L
mutation conditions reduced the beating rate to 69 bpm and
64 bpm, respectively. Furthermore, the reduction in APD90 was
less substantial, being reduced to 149.7 ms and 148.1 ms in the
WT-V307L and V307L conditions, respectively.
In addition to reduced beating rate due to decreased DDR,
the maximum upstroke velocity was reduced by the WT-
V141M mutation condition and to a lesser extent by the
homozygous form of the V307L mutation. Under simulated
parasympathetic modulation by 10 nM ACh, the reduction in
beating rate in V307L mutation conditions was still relatively
minor (Figure 2Bii), whereas pacemaking rate was reduced to
22 bpm in WT-V141M mutation conditions and was abolished
completely by the homozygous V141M expression condition.
Modification of Human Atrial Action
Potentials by SQT2 Mutant IKs
Action potential shortening occurred under all SQT2 mutant
conditions in the baseline CNZ RA model at 1 Hz (Figure 3), as
well as other atrial sub-regions (Supplementary Figure S5). The
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FIGURE 2 | Simulated AP profiles and current traces under WT and SQT2 mutant conditions in human SAN myocytes. Spontaneous pacemaker APs under WT
(lilac, solid line), WT-V141M (red, dashed line), V141M (red, solid line), WT-V307L (turquoise, dashed line), and V307L (turquoise, solid line) conditions (Ai) in the
absence of autonomic modulation, with corresponding current traces for IKs (Aii) and If (Aiii). The beating rate is summarised as a bar chart, without autonomic
modulation (Bi), and with addition of 10 nM acetylcholine (ACh) (Bii). ∗Denotes pacemaking abolished.
V141M mutation abolished the AP plateau phase and reduced
the APD90 from 250.0 ms in the WT condition to 124.7 ms and
85.5 ms under heterozygous and homozygous forms, respectively
(Figure 3Ai). In contrast, the ‘spike and dome’ morphology of
the AP was preserved under V307L mutant conditions, as these
mutations exerted their effects mainly during the terminal phase
of repolarisation. The heterozygous and homozygous forms of
these mutants abbreviated the APD90 to 207.6 ms and 185.4 ms,
respectively. The V141M mutation induces a constitutively
active voltage-independent component of IKs (Hong et al., 2005;
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FIGURE 3 | Simulated AP profiles and current traces under WT and SQT2 mutant conditions in human atrial myocytes. AP profiles in WT, WT-V141M, V141M,
WT-V307L, and V307L conditions at 1 Hz (Ai), as well as corresponding IKs (Aii), ICaL (Aiii), and IKr (Aiv). APD at –70 mV plotted against diastolic interval (DI),
measured using an S1–S2 protocol (Bi), and a bar chart showing maximal slope of restitution (Bii).
Restier et al., 2008). The combination of this and significantly
slowed deactivation resulted in a large outward current during
membrane depolarisation (Figure 3Aii). The V307L mutation,
in contrast, augmented IKs, but did not fundamentally change its
profile.
Figure 3 shows secondary effects of SQT2 KCNQ1 mutants
on L type calcium current, ICaL (Figure 3Aiii) and rapid delayed
rectifier potassium current, IKr (Figure 3Aiv) during APs. The
balance of ionic currents which maintains the plateau phase was
largely abolished in V141M mutation conditions, as the increase
in repolarising IKs overpowered inward ICaL. This also had
the effect of activating IKr to a lesser extent, thus considerably
decreasing its peak current density and contribution to AP
repolarisation. The effects of the V307L mutation on IKs were
less pervasive, with the current profiles of ICaL and IKr being
altered to a smaller extent. Aside from the APD, alterations
Frontiers in Physiology | www.frontiersin.org 6 October 2018 | Volume 9 | Article 1402
fphys-09-01402 October 1, 2018 Time: 14:37 # 7
Whittaker et al. SQT2 and Atrial Fibrillation
TABLE 1 | Single cell AP properties in WT and SQT2 mutant conditions in the FS human SAN model (autorhythmic) and CNZ human atrial cell model (paced at 1 Hz).
Sinoatrial node (SAN) cells
WT WT-V141M V141M WT-V307L V307L
Beating rate (bpm) 73.1 49.6 – 68.7 64.5
APD90 (ms) 151.4 143.4 – 149.7 148.1
APD50 (ms) 125.5 118.1 – 123.9 122.5
MUV (V/s) 7.5 7.2 – 7.5 7.4
DDR (mV/s) 35.5 21.5 – 32.6 29.9
Atrial cells
WT WT-V141M V141M WT-V307L V307L
APD90 (ms) 250.0 124.7 85.5 207.6 185.4
APD50 (ms) 145.9 45.7 30.1 120.0 105.4
APA (mV) 103.0 103.1 102.9 103.3 103.4
MUV (V/s) 212.4 214.7 214.6 214.2 214.4
Abbreviations are as follows: beats per minute (bpm); action potential duration at 50% and 90% repolarisation (APD50 and APD90, respectively); maximum upstroke
velocity (MUV); diastolic depolarisation rate (DDR); and action potential amplitude (APA).
to other AP parameters induced by the SQT2 mutations were
minimal. A summary of single cell simulations (SAN and RA) is
given in Table 1.
All SQT2 mutations investigated shortened the APD across
a range of diastolic intervals (DIs; Figure 3Bi). However, the
V141M and V307L KCNQ1 mutations produced opposing effects
on the maximum slope of restitution. Both heterozygous and
homozygous V141M mutant conditions showed almost no
rate adaptation, with significantly reduced maximal slope of
restitution. In contrast, the V307L mutation conditions increased
the maximal slope of restitution, markedly so in the homozygous
V307L condition. Furthermore, whereas the APD measured in
the WT-V141M condition was considerably shorter than that
measured for the V307L mutation at 1 Hz (124.7 ms vs. 185.4 ms),
at fast pacing rates the restitution curves crossed over, indicating
greater rate adaptation for the V307L mutation.
Tissue Restitution Properties
Restitution curves for the CV, ERP, and WL measured in the
1D strand are shown in Figure 4. None of the SQT2 mutation
conditions investigated considerably affected the CV at pacing
rates slower than 2 Hz, whereas all mutation conditions reduced
the ERP across all basic cycle lengths (BCLs) investigated. As
the excitation WL is given by CV × ERP, the WL was thus
also decreased by SQT2 mutations across all BCLs, indicating
that higher frequency excitations can be supported by SQT2
mutant tissue (investigated in Scroll wave dynamics in 3D
anatomical human atria geometry). The V307L mutation
conditions (the homozygous form in particular) induced beat-
to-beat AP alternans at fast pacing rates, which was evident in
restitution curves for the CV, ERP, and WL.
Spiral Wave Dynamics in Idealised 2D
Sheets of Human Atrial Tissue
The functional impact of KCNQ1-linked SQT2 mutations on re-
entry dynamics was first investigated using an idealised 2D sheet
of human atrial tissue. In the WT condition, an S2 stimulus
delivered at 259 ms following a train of S1 stimuli with a
BCL of 400 ms induced a spiral wave which meandered over
a large area for ∼3.7 s before meeting a tissue boundary and
terminating (Figure 5A and Supplementary Video S1). Both
heterozygous and homozygous forms of the V141M mutation
showed qualitatively similar meandering patterns in tissue. S2
stimuli delivered at 135 ms and 114 ms in WT-V141M and
V141M conditions, respectively, produced spiral waves with
more stationary trajectories (meandering over a smaller area)
which sustained for the complete 5.0 s duration of the simulation
(Figures 5B,C and Supplementary Videos S2, S3). In the WT-
V307L condition, an S2 stimulus applied at 219 ms produced
a spiral wave which also sustained for 5.0 s, meandering
with a hypocycloidal trajectory over a considerably larger
area than under V141M mutation conditions (Figure 5D and
Supplementary Video S4). In the homozygous V307L mutation
condition, however, the S2 stimulus delivered at 201 ms induced
a non-stationary and unstable spiral wave which spontaneously
degenerated into multiple, regenerative wavelets (Figure 5E
and Supplementary Video S5), resembling AF-like electrical
excitations.
Scroll Wave Dynamics in 3D Anatomical
Human Atria Geometry
Use of the phase distribution method resulted in scroll waves
which developed into functional and/or anatomical re-entries
in the 3D anatomical human atria model (Figure 6). In the
WT condition, the initiated scroll wave developed into a
transient re-entry, completing two circuits in the RA before self-
terminating at∼0.6 s (Supplementary Video S6). This precluded
accurate computation of the DF. In the heterozygous WT-V141M
mutation condition, the stationary re-entrant wave pattern
mirrored that observed in the 2D sheet, with re-entry being
driven by a single scroll wave in the RA with a high frequency of
rotation (9.1 Hz; Supplementary Video S7). In the homozygous
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FIGURE 4 | Tissue restitution properties in WT and mutation conditions.
Steady-state restitution of the conduction velocity (CV) (A), effective refractory
period (ERP) (B), and excitation wavelength (WL) (C) against a range of basic
cycle lengths (BCL), measured in the 1D tissue model.
V141M mutation condition, re-entry was driven by a single
stationary scroll wave in the right atrial appendage (RAA),
which had an even higher frequency (10.1 Hz; Supplementary
Video S8). In both cases the re-entry was stable and persistent
(lasting for the full 10.0 s duration of the simulation), and showed
no signs of wave break.
In V307L mutation conditions, re-entrant excitation waves
meandered to a much larger extent than under the V141M
mutation, consistent with observations in the idealised 2D sheet.
In the heterozygous WT-V307L condition, the initiated scroll
wave developed into an irregular excitation pattern, which
eventually anchored to the boundary of the inferior vena cava
(IVC) and sustained for 10.0 s (Supplementary Video S9).
Although the IVC re-entry was persistent, occasional transient
micro re-entrant circuits developed around the RAA. In the
homozygous V307L condition, the initiated scroll wave moved
unpredictably, occasionally breaking and forming multiple
wavelets which meandered and collided, as observed in the
2D sheet. This also ultimately degenerated into a persistent
circuit around the IVC, sustaining for the full 10.0 s of
the simulation (Supplementary Video S10). The DF of re-
entry under heterozygous and homozygous V307L mutation
conditions was 5.3 and 5.8 Hz, respectively.
Effects of Quinidine on APD, ERP, and
Organ-Scale Re-entry Dynamics
As SQTS mutant subunits are expressed heterozygously in vivo,
the effects of different concentrations of the class Ia anti-
arrhythmic drug quinidine were simulated on the cellular
APD/ERP and organ scale re-entry dynamics in WT-V141M and
WT-V307L mutant conditions only. Quinidine restored the APD
to that of the WT level in the WT-V307L but not WT-V141M
condition. However, in both mutation conditions quinidine
prolonged the ERP in a concentration-dependent manner due to
actions on INa, especially in the WT-V307L mutation condition in
which APD was also prolonged. Supplementary Table S7 gives a
summary of APD and ERP prolongation at 1 and 2 Hz, including
that observed in additional simulations in which AF remodelling
was considered.
In 3D re-entry simulations, quinidine was applied after 2.5 s
under heterozygous SQT2 mutation conditions in which re-
entry sustained for 10.0 s in the absence of the drug. Under
WT-V141M conditions, all concentrations of quinidine tested
failed to terminate re-entry, but decreased its frequency of
rotation. Application of both 2 and 5 µM quinidine was
sufficient to terminate re-entrant excitations in the WT-V307L
condition (termination of re-entry by 2 µM quinidine is
shown in Supplementary Video S11), reducing the lifespan
of re-entrant excitation to 7.5 and 4.0 s, respectively. The
mechanism underlying re-entry termination in this condition
was increased ERP by quinidine, which reduced the excitable
gap for anatomically driven re-entry in the anatomical human
atria model. The effects of 2 µM quinidine on re-entry dynamics
and the pECG in WT-V141M and WT-V307L conditions are
shown in Figure 7, as well as the DF for a range of quinidine
concentrations. A summary of the effects of quinidine on SQT2-
mediated atrial arrhythmias under AF remodelling conditions is
shown in Supplementary Figure S13.
DISCUSSION
Main Findings
The major findings of this study are as follows: (1) The
KCNQ1 V141M but not V307L mutation slowed human SAN
pacemaking rate profoundly, through reduced DDR; (2) The
V141M and V307L KCNQ1 mutations shortened the human
atrial APD through distinct mechanisms – the V141M mutation
induced a large instantaneous component of IKs upon membrane
depolarisation which shortened the APD, whereas the V307L
mutation increased IKs primarily during phase 3 repolarisation,
producing more modest APD shortening. The mutations
produced opposing effects on the steepness of restitution; (3)
Both mutations shortened the tissue excitation wavelength
through a reduction in the ERP but not CV across a wide range
of pacing rates; (4) In idealised 2D sheets of human atrial tissue,
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FIGURE 5 | Spiral wave dynamics in 2D human atrial tissue simulations. Snapshots of re-entry are shown at various time points after initiation of a spiral wave in WT
(A), WT-V141M (B), V141M (C), WT-V307L (D), and V307L (E) conditions (i), with corresponding spiral wave core trajectories (ii). Note that the time at which
snapshots were taken differs between mutation conditions.
stationary spiral waves were observed with the V141M mutation,
whereas spiral waves meandered in the heterozygous V307L
mutation condition and wave break occurred in the homozygous
V307L condition. In the 3D anatomical human atria model,
scroll waves self-terminated in the WT condition, whereas all
SQT2 mutation conditions favoured sustenance of re-entry; (5)
Quinidine exerted an anti-arrhythmic decrease in the DF of re-
entrant excitation in heterozygous forms of the SQT2 mutations,
but was effective at terminating scroll waves associated with the
V307L mutation only.
The V141M but not V307L KCNQ1
Mutation Promotes Sinus Bradycardia
In the FS human SAN model, the homozygous form of
the V141M mutation abolished pacemaking, whereas the
heterozygous form reduced the spontaneous beating rate from
73 bpm in the WT condition to 50 bpm. This is in good
agreement with 40–60 bpm (Villafañe et al., 2014) and 50 bpm
(Righi et al., 2016) heart rates reported in SQT2 probands
with the KCNQ1 V141M mutation. Upon application of 10 nM
ACh, pacemaking rate was further reduced to 22 bpm in
the heterozygous V141M mutation condition, and was again
abolished altogether in the homozygous V141M mutation
condition. Previous computational modelling of the V141M
mutation using a rabbit SAN cell model showed abolished
pacemaking in a 1:1 WT:mutant heterozygous WT-V141M
condition (Hong et al., 2005). However, the present study is the
first to reproduce the sinus bradycardia phenotype associated
with the V141M mutation using a biophysically detailed model
of human SAN electrophysiology (Fabbri et al., 2017). Such
alterations to pacemaking activity by the V141M mutation might
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FIGURE 6 | Re-entry dynamics in 3D anatomical human atria. Snapshots of re-entry are shown at various time points after initiation of a scroll wave in WT (A),
WT-V141M (B), V141M (C), WT-V307L (D), and V307L (E) conditions (i), with corresponding first 5.0 s of pseudo ECG (ii). Note that snapshot times differ between
mutation conditions.
be expected to impair the ability of the SAN to pace-and-drive
the surrounding atrium. In relation to this, Hong et al. (2005)
suggested that electrical activity might be initiated in the atrio-
ventricular node in such patients, which could potentially explain
the lack of apparent P waves.
Heterozygous and homozygous forms of the V307L mutation
exerted weaker effects on the SAN pacemaking rate due to less
pervasive effects on IKs – the measured rates of 69 and 64 bpm,
respectively, were within the normal range of heart rates in
humans. It is relevant in this regard that there have been no
reports of sinus bradycardia associated with the V307L mutation
in KCNQ1, with physical examination of the first proband
identified revealing no electrophysiological anomalies other than
a shortened QT interval, as well as the episode of ventricular
fibrillation for which he was admitted to hospital (Bellocq et al.,
2004).
V141M and V307L KCNQ1 Mutations
Shorten Human Atrial APD Through
Different Mechanisms
The V141M and V307L KCNQ1 mutations have been shown
in previous in silico studies to shorten the human ventricular
APD (Adeniran et al., 2017; Lee et al., 2017). In this study,
distinct mechanisms of APD shortening between the mutations
in human atrial cells were identified. Whereas the V141M
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FIGURE 7 | Effects of quinidine on re-entry dynamics under SQT2 mutation conditions. (A) Snapshots of re-entrant scroll waves at various time points after initiation
of a scroll wave in the 3D anatomical human atria under drug-free WT-V141M (i), and WT-V141M + 2 µM quinidine (QUIN) (ii) conditions, with (B) corresponding
pseudo ECG (pECG) recorded during the final 5.0 s. (C) Snapshots of re-entrant scroll waves following re-entry initiation under drug-free WT-V307L (i), and
WT-V307L + 2 µM QUIN (ii) conditions, with (D) corresponding pECGs recorded during the final 5.0 s. Dominant frequencies (DF) calculated from pECGs in control
(c) WT-V141M (E) and WT-V307L (F) conditions and upon application of various concentrations of quinidine. In drug simulations, QUIN was applied at t = 2.5 s.
∗Denotes DF was not calculated as re-entry termination occurred.
mutation conditions caused a more triangular AP morphology
due to increased IKs early during the AP, the V307L mutation
conditions preserved the ‘spike and dome’ morphology of the AP
due to less pervasive effects on IKs (Figure 3 and Supplementary
Figure S5). Furthermore, increased APD dispersion between
cells of the pulmonary veins and left atrium under SQT2
mutation conditions was observed (Supplementary Figure S5),
which may promote high frequency excitation or microreentrant
sources around this junction as a mechanism of AF in this
context.
Different effects of the V141M and V307L KCNQ1 mutations
on the human atrial AP resulted in opposing effects on the
maximum slope of APD restitution – additional simulations in
Supplementary Investigation 2.1 revealed that increased IKs
conductance alone, similar to kinetic changes seen with the
V307L KCNQ1 mutation, increased the slope of restitution,
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whereas constitutively active IKs, as observed for the V141M
KCNQ1 mutation, favoured a decrease in the maximum slope
of restitution. For the KCNQ1 V141M mutation, the slope
was substantially reduced. This is consistent with the study of
Kharche et al. (2012), in which the S140G KCNQ1 mutation
which includes an instantaneous component of IKs similar to that
induced by the V141M mutation, was shown to reduce markedly
the maximum slope of restitution in the CRN human atrial cell
model (Courtemanche et al., 1998). The V307L mutation, on
the other hand, was shown to increase the slope of restitution,
which was also reported in the investigation of the KCNQ1
V307L mutation in human ventricles by Adeniran et al. (2017).
Both of these key findings were reproduced in supplementary
simulations using the human atrial model of Grandi et al. (2011)
(Supplementary Investigation 2.2).
SQT2 Mutations Promote Human Atrial
Arrhythmogenesis
Action potential duration shortening at the cellular level
manifested as a reduction in the ERP across all pacing rates
for both SQT2 mutations. The CV was largely unaffected, and
thus the profound reduction in the excitation WL observed
under SQT2 mutation conditions can be attributed almost
exclusively to the reduction in ERP. This is in contrast to
findings pertaining to KCNJ2-linked SQTS presented in our
previous study (Whittaker et al., 2017b), where reduced WL
was found to be mediated by a decrease in both ERP and CV;
this emphasises the value of multi-scale computational modelling
in elucidating phenotypic differences between different variants
of the SQTS. In idealised 2D sheet simulations, WT tissue did
not support a sustained spiral wave, whereas the V141M and
V307L mutations both favoured sustenance of re-entry. The
V141M mutation produced stationary spiral waves, which were
also observed in the study of Kharche et al. (2012) for the S140G
KCNQ1 mutation which similarly induces an instantaneous
component of IKs (Chen et al., 2003). In contrast, the V307L
mutation conditions produced spiral waves which meandered
to a larger extent, spontaneously breaking and forming multiple
wavelets in the homozygous condition. This mutant form showed
a steep (>1) maximum slope of restitution and alternans,
which are known to promote electrical instability in cardiac
tissue.
In 3D human atria simulations the V141M mutation produced
stationary scroll waves, even in the presence of electrical
and anatomical heterogeneities. The persistent nature of re-
entry in this condition compared to the WT, in which scroll
waves quickly self-terminated, can be explained in terms
of tissue excitation WL. Increased IKs associated with the
V141M mutation abbreviated APD and ERP, which consequently
reduced the excitation WL. This is a measure of the spatial
requirement for a functional re-entrant circuit, and thus
reduced WL facilitates conduction of high rate excitation
waves within a limited atrial mass (Kharche et al., 2012;
Whittaker et al., 2017b). The findings of this study thus
substantiate a causative link between the KCNQ1 V141M
mutation and multiple reports of recalcitrant AF in affected
patients (Hong et al., 2005; Villafañe et al., 2014; Righi et al.,
2016). There have been no reported episodes of AF consequent
to the V307L mutation to date. However, as the number of
V307L SQTS patients is very small (Hu et al., 2017), and AF can
be paroxysmal and/or asymptomatic, atrial arrhythmias arising
from this mutation cannot be ruled out. The phenotypically
accurate computational models in this study predicted that
the V307L KCNQ1 mutation facilitates sustenance of re-
entrant excitations in the human atria, albeit with decreased
stability, stationarity, and DF compared to V141M mutation
conditions.
Quinidine Controls Rate but not Rhythm
of Arrhythmic Atrial Excitations in SQT2
To date, no specific blockers of IKs are in clinical use (Hancox
et al., 2018). The current front-line pharmacological treatment
for hERG-related SQTS patients is the class Ia anti-arrhythmic
drug quinidine (Gaita et al., 2004; Hu et al., 2017) – a multi-
channel blocker which exerts a mild blocking effect on IKs. Under
the WT-V141M mutation condition, quinidine reduced the DF
of re-entry, but did not terminate re-entrant activity at any of
the concentrations tested. This is consistent with the findings
of Righi et al. (2016) who reported that recurrent AF associated
with the KCNQ1 V141M mutation was unresponsive to multiple
anti-arrhythmic agents (failing to revert to sinus rhythm),
including (hydro)quinidine (Righi et al., 2016). Re-entrant
excitations in the human atria under the WT-V307L mutation
condition, on the other hand, were responsive to quinidine
therapy, with concentrations of 2 and 5 µM terminating
re-entry in our model. The findings of the 3D simulations
were consistent with cellular level APD/ERP predictions, in
which quinidine was shown to effectively restore the APD
only in the WT-V307L condition, but consistently increased
the ERP in a dose-dependent manner under both mutation
conditions (including in the presence of AF remodelling;
Supplementary Table S7). These results suggest that in the
setting of SQT2-mediated atrial arrhythmias, quinidine may
be a more effective strategy for rate control than rhythm
control.
It has been reported previously that quinidine was ineffective
at prolonging the QT interval in the setting of KCNQ1 V141M-
mediated SQT2 (Righi et al., 2016). As SQT2 is caused by a gain-
of-function in IKs, it is likely that an anti-arrhythmic drug which
blocks IKs to a larger degree is required to reverse the phenotype.
In a previous computational study of SQT2 in the human
ventricles by Adeniran et al. (2017), IKs block was demonstrated
to effectively terminate re-entrant excitations associated with the
V307L mutation in KCNQ1, as well as to restore the APD/QT
interval in both V307L and V141M conditions. Selective IKs block
as a potential therapeutic strategy has also been supported in an
experimental study (Campbell et al., 2013). IK1 has also been
suggested to be a potential therapeutic target in the context of
V141M-mediated SQT2, based on the reduction in transmural
APD heterogeneity and prolongation of the QT interval observed
following IK1 block in computational models of the human
ventricles (Lee et al., 2017).
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Limitations
There are a number of limitations associated with the simulations
presented in this study. Potential limitations of the 3D anatomical
human atria, regional cell models, and drug binding models have
been discussed in our previous publications (Colman et al., 2013;
Ni et al., 2017; Whittaker et al., 2017a,b). Specific limitations
to be considered here are as follows. (1) Previous in vitro
experiments have shown that blocking potency of IKs blockers
can be reduced for recombinant channels containing KCNQ1-
linked SQT2 mutations, as observed for chromanol 293B (Lerche
et al., 2007; El Harchi et al., 2010) but not mefloquine (El
Harchi et al., 2010). Whether or not quinidine block of IKs is
altered by the SQT2 mutations was not considered due to lack
of experimental data, although even at the highest concentration
tested (5 µM), the block of IKs was small (∼10%). (2) Late
sodium current, INaL, is not present in the CNZ model. Quinidine
block of INaL could potentially reduce the APD prolongation
observed in this study, although the presence and contribution
of INaL in human atrial myocytes at physiological temperature
remains to be confirmed (Poulet et al., 2015). (3) There are
currently no data on the presence or absence of electrical
and/or structural remodelling in the SQTS. Inclusion of these
factors was considered in the Supplementary Material for
completeness – these additional simulations do not change the
fundamental mechanistic conclusions drawn in this study. (4)
The heterozygous formulations of SQT2 mutants used in this
study relied on the simplifying assumption that both V141M
and V307L IKs behave similarly to a 50:50 mixture of WT and
mutant channels. In reality, the channel populations may be more
complex, with each channel consisting of both WT and mutant
KCNQ1 subunits. In our previous study (Zhang et al., 2008),
the effects of varying mutant subunit composition in SQT2 were
investigated, based on different expression/co-expression ratios
used by Bellocq et al. (2004) in the original paper describing
the V307L KCNQ1 mutation. In that study (Zhang et al., 2008),
it was found that the degree of shortening of the ventricular
APD and QT interval increased progressively with the level of
V307L expression. Furthermore, in our previous study (Adeniran
et al., 2017), the heterozygote formulation used for V307L was
shown to reproduce QT interval shortening and increased T
wave associated with the SQTS phenotype, thus supporting
the approach adopted in this study. (5) The effects of human
atrial contraction were not considered, which could feasibly
modulate the atrial AP under SQTS conditions (Whittaker et al.,
2015), and thus re-entrant electrical activity. (6) Scroll wave
dynamics in the 3D anatomical human atria model should be
interpreted with caution, as dynamic behaviour of re-entrant
excitations, including wave break, can depend critically on initial
conditions, especially in such a complex geometry (Benson et al.,
2007).
CONCLUSION
The multi-scale computational approach adopted in this study
allowed phenotypic differences associated with two distinct
KCNQ1-linked SQTS mutations to be assessed. Furthermore, the
response of arrhythmic excitation waves to clinically relevant
doses of quinidine under SQT2 conditions was probed. The
simulations substantiated a causative link between the KCNQ1
V141M mutation and an AF/sinus bradycardia phenotype
which has been observed clinically. In addition, the V307L
mutation in KCNQ1 was predicted to promote human atrial
arrhythmogenesis whilst not significantly affecting pacemaking
function. Quinidine was shown to be useful for rate control of
atrial arrhythmias associated with SQT2, but appears likely to be
less reliable for rhythm control in this setting.
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